SCHEMBL3041660

SCHEMBL3041660

Cc1cnc(Cl)c(C(=O)O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
LMNA P02545 2/20 0.46
KEAP1 Q14145 1/20 0.44
NFE2L2 Q16236 1/20 0.44
GABRP O00591 1/20 0.43
GABRD O14764 1/20 0.43
GABRA1 P14867 1/20 0.43
GABRB1 P18505 1/20 0.43
GABRG2 P18507 1/20 0.43
GABRB3 P28472 1/20 0.43
GABRA5 P31644 1/20 0.43
GABRA3 P34903 1/20 0.43
GABRA2 P47869 1/20 0.43
GABRB2 P47870 1/20 0.43
GABRA4 P48169 1/20 0.43
GABRE P78334 1/20 0.43
GABRA6 Q16445 1/20 0.43
GABRG1 Q8N1C3 1/20 0.43
GABRG3 Q99928 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31430855 1.00 KDR (0.47) KDRSMN1; SMN2LMNAKEAP1NFE2L2
Nitrous Acid SCHEMBL27969638 0.93 KDR (0.43) KDRSMN1; SMN2LMNAKEAP1NFE2L2
SCHEMBL28007123 0.84 KDR (0.50) KDRSMN1; SMN2LMNAHCAR2KDM4E
SCHEMBL13964183 0.84 KDR (0.47) KDRSMN1; SMN2LMNAHCAR2KDM4E
SCHEMBL25841888 0.82 PARP1 (0.50) KDR
SCHEMBL2280055 0.80 FTO (0.43) SMN1; SMN2LMNAKEAP1NFE2L2GABRP
SCHEMBL3732128 0.79 ATM (0.47) KDRSMN1; SMN2LMNAKDM4EALDH1A1
SCHEMBL8828399 0.79 PIK3C3 (0.49) KDRALDH1A1KMT2AHPGD
SCHEMBL612856 0.79 KDM4E (0.48) SMN1; SMN2GABRPGABRDGABRA1GABRB1
SCHEMBL915781 0.79 SMN1; SMN2 (0.48) SMN1; SMN2LMNAKEAP1NFE2L2HCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12508268-B2 Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy AUCKLAND UNISERVICES LIMITED (NZ) 2025-12-30 US disclosed
US-20250066378-A1 SPIRO-OXAZOLONES HOFFMANN-LA ROCHE INC. (US) 2025-02-27 US disclosed
CN-118126043-B PLK4 inhibitor with high selectivity and preparation method and application thereof 沈阳药科大学 2025-01-28 CN disclosed
WO-2025007784-A1 HETEROAROMATIC RING COMPOUND, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2025-01-09 WO disclosed
US-12162887-B2 Spiro-oxazolones HOFFMANN-LA ROCHE INC. (US) 2024-12-10 US disclosed
US-20240285641-A1 INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2024-08-29 US disclosed
WO-2024129395-A1 BTK INHIBITORS GWYNANT THERAPEUTICS, INC. (US) 2024-06-20 WO disclosed
WO-2024114574-A1 HIGH-SELECTIVITY PLK4 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 沈阳药科大学 2024-06-06 WO disclosed
CN-118126043-A PLK4 inhibitor with high selectivity and preparation method and application thereof 沈阳药科大学 2024-06-04 CN disclosed
CN-117618423-A Inhibitors of tryptophan dioxygenase (IDO 1 and TDO) and their use in therapy 奥克兰联合服务有限公司 2024-03-01 CN disclosed
US-20050020611-A1 Compounds PFIZER INC. 2005-01-27 US disclosed
US-5405826-A Herbicidal pyridopyridazinones and pyridopyridazinethiones RHONE POULENC AGRICULTURE LIMITED (GB) 1995-04-11 US disclosed
US-5393730-A Preemergence, postemergence herbicides RHONE-POULENC AGRICULTURE LTD. (GB) 1995-02-28 US disclosed
CN-1098096-A New nicotinic acid derivatives RHONE POULENC AGRICULTURE (GB) 1995-02-01 CN disclosed
EP-0606843-A1 Nicotinic acid derivative RHONE POULENC AGRICULTURE LTD. (GB) 1994-07-20 EP disclosed
CN-1076448-A Novel herbicide R P AGRICULTURE LTD (GB) 1993-09-22 CN disclosed
EP-0555957-A1 Pyrido 2,3-d pyridazine derivatives as herbicides RHONE-POULENC AGRICULTURE LTD. (GB) 1993-08-18 EP disclosed
EP-0482481-A1 Method for the preparation of 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepines BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 1992-04-29 EP disclosed
EP-0295833-A1 Aromatic-Spiropiperidine oxazepinones (and thiones) A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) 1988-12-21 EP disclosed
US-4746655-A ANTIHISTAMINES A. H. ROBINS COMPANY, INCORPORATED (US) 1988-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020611-A1 Compounds NQO1, NAMPT, NNT KDR 3071/4885SMN1; SMN2 2287/4885LMNA 915/4885
US-20240285641-A1 INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY IDO1, TDO2, IDO2 KDR 3759/4885SMN1; SMN2 3658/4885LMNA 4683/4885
US-12508268-B2 Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy IDO1, IDO2, TDO2 KDR 922/4885SMN1; SMN2 3177/4885LMNA 4304/4885
US-12162887-B2 Spiro-oxazolones AVPR1A, AVPR1B, AVPR2 KDR 1094/4885SMN1; SMN2 3497/4885LMNA 3114/4885
US-20250066378-A1 SPIRO-OXAZOLONES AVPR1A, AVPR1B, AVPR2 KDR 1094/4885SMN1; SMN2 3497/4885LMNA 3114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.